Effects of high dose, daily, oral Vitamin D3 therapy in patients with psoriasis.

INTERVENTION: Intervention1: oral cholecalciferol 60000 IU once daily for 10 days followed by 30000 to 40000 IU once daily: Oral cholecalciferol 60000 IU once daily for 10 days followed by 30000 to 40000 IU once daily for the subsequent treatment period with dose adjustment according to body weight and BMI PASI response serum calcium and PTH levels. Treatment will continue for 6 months along with conventional psoriasis therapy. Magnesium glycinate 250 mg daily and multivitamin and multimineral supplementation will also be provided as specified in the protocol. Control Intervention1: Routine treatment of Psoriasis with Apremilast or Acetretin or methotrexate: Routine treatment of Psoriasis with Apremilast or Acetretin or methotrexate for controls CONDITION: Health Condition 1: L400‐ Psoriasis vulgaris PRIMARY OUTCOME: Number or Percentage of patients achieving a reduction of fifty percent in PASI score from baseline Percentage and number of patients with the change from baseline of PGA score. ; Change in VAS for itching from baseline to End point with the number of patients achieving it. ; Change from baseline of Dermatology Quality of Life Index DLQI scoreTimepoint: Day 0 ; Day 15 ; Day 30 ; Day 60 ; Day 90 ; Day 120 ; Day 150 ; Day 180 SECONDARY OUTCOME: Percentage & number of patients with the change from baseline of PGA score. ; Change in VAS for itching from baseline to End point with the number of patients achieving it. ; Change from baseline of Dermatology Quality of Life Inde XDLQI scoreTimepoint: Day 0 ; Day 15 ; Day 30 ; Day 60 ; Day 90 ; Day 120 ; Day 150 ; Day 180 INCLUSION CRITERIA: ‐Patients of either gender above 18 years of age diagnosed with moderate to severe Palmo‐plantar or Plaque Psoriasis ‐Treatment naive patients. ‐Subjects willing to sign the Informed Consent Form ‐Subject able to attend all scheduled visits and to comply with the trial protocol